Abstract: Disclosed are analogs of elamipretide (MTP-131). The compounds are useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.

Abstract: In fibrotic lung fibroblasts, basal levels of p53 protein (and miR-34a) are markedly suppressed, leading to reduced p53-mediated inhibition of uPA and uPAR, or concurrent induction of PAI-1. These changes contribute to excessive FL-fibroblast proliferation and production of extracellular matrix (ECM), and, therefore, pulmonary fibrosis. These processes are reversed by treating the cells, and treating subjects suffering from idiopathic pulmonary fibrosis (IPF) with the small organic molecule nutlin-3a (NTL) or with a peptide, CSP-4 (SEQ ID NO:1), or variants or derivatives or multimers of this peptide, which increase p53 levels by inhibiting MDM2-mediated degradation of p53 protein. Use of these compounds serves as a new approach to the treatment of IPF, as they restore p53 expression and p53-mediated changes in the uPA-fibrinolytic system in FL-fibroblasts and restrict production and deposition of ECM.

Abstract: The invention relates to a novel reconstitution composition, a pharmaceutical composition and kit of parts comprising said reconstitution composition. The invention further relates to a method of treatment using said pharmaceutical composition and/or the pharmaceutical composition for use as a medicament. Also provided is a method for reconstituting dried peptides and a method for preparing a pharmaceutical composition using the reconstitution composition of the invention.

Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.

Abstract: The present disclosure provides click-crosslinked hydrogels and methods of use.

Abstract: A compound is provided comprising a melanocortin 1 receptor (MC1R) targeting peptide (MC1RTP), a radiolabeling group, and a linker joining the MC1RTP to the radiolabeling group. The MC1RTP is linear or cyclized, and comprises a sequence of Formula I or Formula II: Xaa1-Xaa2a-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7a (I) or Xaa1-Xaa2b-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7b (II). Xaa1 is L-/D-Nle, L-/D-Nle, L-/D-Ala, L-/D-Leu, L-/D-Ile, D-Ile, L-/D-Cys, L-/D-Met, L-/D-Phe, L-/D-Trp, L-/D-Val, L-/D-Nal, L-/D-2-Nal, Gly, L-/D-?-aminobutryic acid, L-/D-norvaline, or L-/D-homonorleucine. Xaa2a and Xaa7b are L-/D-Cys, L-/D-Asp, L-/D-Glu, L-/D-2-Aad, L-/D-3-Aad, L-/D-Pra, L-/D-Hpg, or L-/D-Bpg. Xaa2b and Xaa7a are L-/D-Cys, L-/D-Lys, L-/D-Orn, L-/D-Dab, L-/D-Dap, L-/D-Lys(N3), L-/D-Orn(N3), L-/D-Dab(N3), L-/D-Dap(N3), L-/D-2-(5?-azidopentyl)alanine, or L-/D-2-(6?-azidohexyl)alanine. Xaa3 is L-/D-His, Pro, beta-(1,2,3-triazol-4-yl)-L-alanine, beta-(1,2,3-triazol-4-yl)-D-alanine, 1,2,4-triazole-3-alanine, or 1,2,4-triazole-3-D-alanine.

Abstract: The present disclosure belongs to the field of pharmaceutical preparations and relates to the design of a series of lipophilic derivatives by using wild-type penetrating peptide penetratin. These penetratin derivatives have a strong ability to penetrate the ocular tissues and do not cause ocular tissue toxicity. As ocular absorption enhancers, non-invasive routes could be used to achieve intraocular drug delivery and increase the ocular bioavailability of drugs. These penetratin derivatives and the ophthalmic drug delivery system constructed by them are used for eye drop administration, which could replace the intraocular injection with poor patients compliance, which greatly enhances the convenience and safety of the treatment of intraocular and fundus diseases.

Abstract: Methods and compositions for delivering medicine and other substances to the brain and the body via the cribriform plate using foamable compositions are described. Methods and compositions for improving nasal hygiene and moisturizing the nasal cavity using foamable compositions are also described.

Abstract: Eleven synthetic neurokinin A peptide analogs are provided as therapeutic compounds for inducing voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). This control over when and where individuals void offers a drastic improvement in quality of life.

Abstract: Disclosed are various crystalline salt forms of D-Arg-Dmt-Lys-Phe-NH2.

Abstract: A sheet pack comprising an absorbent layer impregnated with a treatment composition containing at least one ingredient that when topically applied to skin stimulates a gene that is variably expressed over a 24 hour period in native untreated skin cells; the sheet pack contained in a package with user instructions to topically apply the sheet pack to the skin at a time when the gene that is stimulated by the ingredient is being maximally expressed in native untreated skin cells; and methods for treating skin and methods for making a sheet pack.

Abstract: The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/or impairment, pain, and traumatic brain injury.

Abstract: The present invention is directed to a peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C?-terminus of PAR-1, or an active variant thereof and a protease-disabling moiety. The present invention is further directed to pharmaceutical compositions comprising the peptide conjugate and use thereof for treating diseases and disorder associated with excessive PAR-1 activity.

Abstract: Compositions of the invention comprise 8-oxoguanine glycosylase (OGG1) and SIRT6 activating peptide G-A-G-V-S-A-E-NH2. Compositions of the invention exhibit anti-aging effects by promoting the repair of skin cell DNA and/or by protecting skin cell DNA from UV damage.

Abstract: Disclosed is a method of treating, reducing, or preventing pruritis in a mammal, the method comprising administering at least one natriuretic polypeptide b (Nppb) blocking agent to a mammal in an amount effective to treat or prevent pruritis in the mammal. An in vitro method of identifying a compound that inhibits Nppb activity is also disclosed.

Abstract: Methods for identifying compounds that positively regulate connexin 43 hemichannels.

Abstract: The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease.

Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.

Abstract: Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods.

Abstract: Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent.

Abstract: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.

Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.

Abstract: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 ?m to about 20 ?m.

Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.

Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).

Abstract: A therapeutic composition for treating brain injury comprising a polyarginine peptide of from 5 to 9 arginines, and further comprising 1 or more terminal cysteines. The composition is administered in therapeutically effective dosages prophylactic ally as soon as possible post-injury in treating neuronal injury.

Abstract: Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.

Abstract: AV?6 peptide ligands, functional variants thereof and their nucleic acids encoding them are disclosed with their uses in the treatment and imaging of AV?6 mediated diseases.

Abstract: A finished pharmaceutical product adapted for oral delivery of an aromatic-cationic peptide, wherein the product comprises a therapeutically effective amount of the peptide; at least one pharmaceutically acceptable pH-lowering agent; and at least one absorption enhancer effective to promote bioavailability of the active agent. The product is adapted for use in a method for enhancing the bioavailability of a therapeutic aromatic-cationic peptide delivered orally.

Abstract: A fusion peptide including a hydrophobic peptide and a basic peptide, a pharmaceutical composition including the fusion peptide, a cell membrane penetrating conjugate including the fusion peptide and a substance of interest, and a method for intracellular delivery of a substance of interest using the fusion peptide.

Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.

Abstract: The invention relates to the field of biochemistry and concerns of recombinant method for production of peptides and the resulting peptides. In particular, the invention relates to peptides with the following general formula: A-Thr-Lys-Pro-B-C-D-X, where: A—0, Met, Met (O), Thr, Ala, His, Phe, Lys, Gly B—0, Gly, Asp, Trp, Gin, Asn, Tyr, Pro, Arg C—0, Arg, Phe, Tyr, Gly, His, Pro, Lys D—0, Val, Gly, Tyr, Trp, Phe, His X—OH, OCH3, NH2, where 0 is no amino acid residue, provided that if A?0, then B and/or C and/or D?0, if B?0, then C and/or D?0, excluding the peptides Phe-Thr-Lys-Pro-Gly, Thr-Lys-Pro-Pro-Arg, Thr-Lys-Pro-Arg-Gly.

Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.

Abstract: Compounds of general formula (I): Ri—Wn—Xm-AAi-AA2-AA3-AA4-AA5-AA6-Yp—Zq—R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, pigmentation disorders and angiogenic skin disorders, and in processes of treatment and/or care of the skin and/or mucous membranes.

Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: Compounds of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-Yp—Zq—R2, their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.

Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

Abstract: The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e. Interleukin-17, by providing said nutritional compositions to a target subject.

Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.

Abstract: The invention provides sustained release formulations comprising a C5a receptor antagonist. In certain embodiments the sustained-release formulations include microparticles that comprise a complement C5aR antagonist and a biodegradable polymeric matrix. Methods of treatment comprising the sustained release formulations of the invention are also provided.

Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder.

Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, andor lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.

Abstract: Sirt5, a mitochondrial Sirtuin, has been identified herein as an efficient demalonylase and desuccinylase. Disclosed herein are assays to identify Sirt5 modulators based on this robust enzymatic activity. Sirt5-specific modulators can be used study the biological function of Sirt5 and to target Sirt5 activities in treating human diseases.

Abstract: Peptide compounds of general formula (I) R1-(AA)n-X1—X2—X3-Asp-Leu-Lys-Lys-X4—X5-(AA)p-R2, cosmetic or pharmaceutical compositions comprising at least one peptide compound of general formula (I) in a physiologically acceptable medium, and methods for cosmetic treatment of skin are disclosed. The peptide compounds of general formula (I) were demonstrated to be agents making it possible to influence the pigmentation of the skin and skin appendages, by ensuring optimal transfer of the melanosomes to the keratinocytes, so as to make the skin tone uniform owing to an effect on the SCF/c-Kit signaling pathway. The compounds, compositions, and methods treat or attenuate age-related pigmentation defects and the effects of photoaging on the skin.

Abstract: A method for repairing DNA damage in human keratinocytes by applying to the keratinocytes a composition comprising at least one CLOCK or PER1 gene activator and at least one DNA repair enzyme.

Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.

Abstract: The invention provides for a receptor, capable of binding to a target molecule, linked to a hygroscopic polymer or hydrogel; and the use of this receptor in a device for detecting the target molecule in a gaseous and/or liquid phase. The invention also provides for a method for detecting the presence of a target molecule in the gas phase using the device. In particular, the receptor can be a peptide capable of binding a 2,4,6-trinitrotoluene (TNT) or 2,4,-dinitrotoluene (DNT).

Abstract: Peptides from the MUC1 cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.

Abstract: Disclosed is an oligopeptide for treating liver fibrosis and/or hepatitis B and/or improving liver function. The oligopeptide is obtained by reflux extraction via water, ethanol precipitation and isolation through a cation exchange resin column and a gelatinous resin column from a turtle shell. Pharmaceutically conventional excipients can be added to the oligopeptide prepared according to the present invention to prepare various dosage forms. The oligopeptide has good efficacy in treating liver fibrosis and improving liver function.